Psychedelic Therapy Access in Europe: Comparison
Compare ketamine and esketamine licensing, reimbursement, and patient access pathways across selected European markets.
Europe access comparison
This resource provides a side-by-side view of ketamine and esketamine access pathways across selected European markets, with a focus on licensing status, reimbursement, and practical availability.
Psychedelic Therapy Access in Europe
Detailed comparison of ketamine and esketamine licensing, reimbursement status, and patient access across selected European markets.
| Country | Ketamine | Esketamine (Spravato) | ||||
|---|---|---|---|---|---|---|
| Licensed | Reimbursement status | Level of patient access | Licensed | Reimbursement status | Level of patient access | |
| Germany | No | No statutory health insurance coverage; individual reimbursement applications via insurers. | Very limited (individual hospitals). | Yes | Reimbursed; positive HTA outcome (G-BA/IQWiG). | Limited, but expanding. |
| United Kingdom | No | No national reimbursement status or routine NHS funding. | Very limited (private clinics, select NHS trusts). | Yes | Not recommended in England and Wales (NICE); recommended in Scotland (SMC). | Extremely limited in England and Wales; private clinic access available. |
| Netherlands | No | Insurance coverage for clinical support costs. | Limited, but expanding. | Yes | Approved for coverage under basic health insurance (2021). | Very limited (few dozen patients yearly). |
| Czech Republic | No | Some insurance coverage with patient co-payment. | Established clinical access since 2020. | Yes | Exceptional reimbursement for TRD; standard reimbursement approved at end of 2024. | Limited, but expanding with major insurance coverage. |
Germany
Ketamine
No statutory health insurance coverage; individual reimbursement applications via insurers.
Very limited (individual hospitals).
Esketamine (Spravato)
Reimbursed; positive HTA outcome (G-BA/IQWiG).
Limited, but expanding.
United Kingdom
Ketamine
No national reimbursement status or routine NHS funding.
Very limited (private clinics, select NHS trusts).
Esketamine (Spravato)
Not recommended in England and Wales (NICE); recommended in Scotland (SMC).
Extremely limited in England and Wales; private clinic access available.
Netherlands
Ketamine
Insurance coverage for clinical support costs.
Limited, but expanding.
Esketamine (Spravato)
Approved for coverage under basic health insurance (2021).
Very limited (few dozen patients yearly).
Czech Republic
Ketamine
Some insurance coverage with patient co-payment.
Established clinical access since 2020.
Esketamine (Spravato)
Exceptional reimbursement for TRD; standard reimbursement approved at end of 2024.
Limited, but expanding with major insurance coverage.
How to use this comparison
- Use this table as a market-scoping reference when prioritising evidence, payer, and service-readiness planning.
- Re-validate entries before publication decisions, as reimbursement conditions can change quickly across jurisdictions.